dipyridamole has been researched along with Osteomalacia in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Osteomalacia: Disorder caused by an interruption of the mineralization of organic bone matrix leading to bone softening, bone pain, and weakness. It is the adult form of rickets resulting from disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoshino, C | 1 |
| Satoh, N | 1 |
| Sugawara, S | 1 |
| Kuriyama, C | 1 |
| Kikuchi, A | 1 |
| Ohta, M | 1 |
1 other study available for dipyridamole and Osteomalacia
| Article | Year |
|---|---|
Sporadic adult-onset hypophosphatemic osteomalacia caused by excessive action of fibroblast growth factor 23.
Topics: Age of Onset; Bone Density Conservation Agents; Dipyridamole; Fibroblast Growth Factor-23; Fibroblas | 2008 |